Mesenchymal stem cells and their secretome - candidates for safe and effective therapy for systemic lupus erythematosus. Małgorzata Popis, Aneta Konwerska, Małgorzata Partyka, Maria Wieczorkiewicz, Sylwia Ciesiółka, Katarzyna Stefańska, Julia Spaczyńska, Afsaneh Golkar-Narenji, Michal Jeseta, Dorota Bukowska, Paul Mozdziak, Marta Dyszkiewicz-Konwińska.The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases. Chao Yang, Mingjun Wu, Min You, Yu Chen, Maowen Luo, Qiang Chen.Cell Communication and Signaling 2022, 20 Ameliorating role of microRNA-378 carried by umbilical cord mesenchymal stem cells-released extracellular vesicles in mesangial proliferative glomerulonephritis. Wenbiao Chen, Feng Zhang, Xianliang Hou, Huixuan Xu, Donge Tang.More importantly, the alterative expression of IFN-γ, the improvement of migration ability of UC-MSCs, the regulation of Th1/Th2 balance, and the changes of antibodies secretion in B cell might be involved in its mechanisms. It is necessary for clinical treatment to pre-evaluated concomitant application of UC-MSCs with HCQ. Our results indicate that HCQ plays a double-edged role in UC-MSCs. HCQ pretreatment caused a significant decrease of TNF-α and MCP-1 secretion and an increase of IL-1β and CXCL10 release from UC-MSCs. Results showed that after administration of UC-MSCs pretreated by HCQ, CXCR3 expression in renal tissues, serum IL-2, and IgM levels decreased significantly, and serum IL-10 level increased significantly. To test the role of HCQ in UC-MSCs, MRL/lpr mice and SLE patients’ peripheral blood were used in vivo and in vitro. However, HCQ-pretreated UC-MSCs showed significant improvements of renal morphology and function more rapidly than that of UC-MSCs and HCQ alone. Surprisingly, although the treatment of both HCQ and UC-MSCs could ameliorate renal damage separately, the presence of HCQ decreased unexpectedly the therapeutic effects of UC-MSCs through interfering expression of IFN-γ. In this study, HCQ and UC-MSCs were used in MRL/lpr mice. However, the effect of HCQ on UC-MSCs in lupus nephritis (LN) has not been investigated. Hydroxychloroquine (HCQ) and human umbilical cord-derived mesenchymal stem cells (UC-MSCs) were used to treat systemic lupus erythematosus (SLE), respectively.
0 kommentar(er)
